FIELD: pharmaceutics.
SUBSTANCE: invention relates to morphinan derivative represented by the general formula (I) and having agonistic activity of opioid δ-receptor, as well as to a pharmaceutical composition containing morphinan derivative of the general formula (I).
EFFECT: obtaining morphinan derivative.
128 cl, 6 dwg, 47 ex, 9 tbl
Title | Year | Author | Number |
---|---|---|---|
SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
CONDENSED QUINOLINE DERIVATIVE AND USE THEREOF | 2005 |
|
RU2384571C2 |
SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
MACROCYCLIZATION REACTIONS AND INTERMEDIATE COMPOUNDS AND OTHER FRAGMENTS SUITABLE FOR PREPARING ANALOGUES OF HALICHONDRIN B | 2014 |
|
RU2710545C2 |
PENTACYCLIC HETEROCYCLIC COMPOUND | 2020 |
|
RU2815382C2 |
SPIROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2781639C2 |
RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
PROPENOATE BETULIN DERIVATIVES | 2012 |
|
RU2613554C2 |
Authors
Dates
2021-12-21—Published
2016-03-17—Filed